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Purpose. To date, no study has examined a population-based registry to determine the impact of multiple malignancies on survival
of bladder cancer patients. Our experience suggests that bladder cancer patients with multiple malignancies may have relatively
positive outcomes. Materials & Methods. We utilized data from the Surveillance Epidemiology and End Results (SEERs) database
to examine survival between patients with only bladder cancer (BO) and with bladder cancer and additional cancer(s) antecedent
(AB),subsequent(BS),orantecedentandsubsequenttobladdercancer(ABS).Results.Analysesdemonstrateddiminishedsurvival
among AB and ABS cohorts. However, when cohorts were substratiﬁed by stage, patients in the high-stage BS cohort appeared
to have a survival advantage over high-stage BO patients. Conclusions. Bladder cancer patients with multiple malignancies have
diminished survival. The survival advantage of high-stage BS patients is likely a statistical phenomenon. Such ﬁndings are
important to shape future research and to improve our understanding of patients with multiple malignancies.
Copyright © 2009 Joshua R. Ehrlich et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Patients with cancer are at an increased risk for developing
additional subsequent primary tumors [1]. One recent study
using Surveillance Epidemiology and End Results (SEERs)
data found that of cancer patients alive as of January 1,
2001,nearly8%werediagnosedwithmorethanoneprimary
malignant tumor between 1975 and 2001 [2]. This statistic
underscores the pervasive nature of multiple malignancies
and raises important questions regarding etiology, treatment
decisions, demographics, and outcomes.
While several investigations have focused on assessing
risk factors for developing subsequent primary malignan-
cies, long-term outcomes data on patients with multiple
malignancies are lacking. Speciﬁcally, to our knowledge,
no study has examined a large cohort of bladder cancer
patients to compare survival between those with single and
multiple cancers. Based on our own clinical experience, we
hypothesized that patients with bladder cancer and multiple
malignancies may have improved outcomes compared with
their single malignancy counterparts. Aside from clinical
observations, this hypothesis stemmed, in part, from the
question: if a patient survives one malignancy, is there
perhaps something inherently diﬀerent in their immune
system or other genetic surveillance mechanisms that might
confer improved survival?
Bladder cancer is, in fact, an immunoresponsive malig-
nancy. Numerous studies have demonstrated the eﬃcacy
of bacillus Calmette-Guerin immunotherapy in eradicat-
ing bladder tumors and delaying recurrence and stage
progression of noninvasive bladder cancer [3, 4]. While
not completely understood, the underlying mechanism
seems to involve a vigorous cellular immune response with
the interaction of sensitized T-lymphocytes and activated
macrophages through cytokine production to kill and pre-
vent growth of cancer cells [5, 6]. Immune surveillance
in bladder cancer patients with multiple malignancies may
indeed be diﬀerent from patients with only bladder cancer2 Advances in Urology
only, and such diﬀerences may manifest in population-
based data relating to survival. An investigation comparing
long-term survival among patients with single and multiple
cancers might provide insight into the biological, genetic
andimmunologicalfactorsthatinﬂuencethedevelopmentof
multiple cancers, treatment response, and cancer survival. In
addition, it may provide an improved understanding of the
impact of an aging population, increased cancer screening,
and improved imaging techniques in detecting additional
cancers.
Because our own cohort of bladder cancer patients with
multiple malignancies is relatively small, we employed data
from the SEER program database to investigate diﬀerences in
survival from bladder cancer among patients with single and
multiple malignancies. Survival among patients diagnosed
with only bladder cancer was compared with patients
diagnosed with bladder cancer and one or more additional
subsequent or antecedent nonbladder malignancies. We
compared these cohorts, adjusting for risk and demographic
factors in order to determine trends in survival from bladder
cancer.
2. Methods
All analyses were carried out using SEER data compiled
from 1973 to 2004. The SEER Program collects cancer
incidence data from population-based cancer registries that
covered greater than 10% of the US population in 2000
[1]. A single malignancy cohort was deﬁned to consist
of all patients who received a diagnosis of bladder cancer
and no additional cancer diagnoses (BO). The cohort of
patients with both bladder and nonbladder malignancies
was partitioned according to whether the nonbladder
malignancy occurred antecedent (AB), subsequent (BS),
or both antecedent and subsequent (ABS) to the diagnosis
o fb l a d d e rc a n c e r( Table 1). All nonbladder malignancy
sites tracked in SEER were included in the analyses
(see: http://seer.cancer.gov/siterecode/icdo3 d01272003/);
nonmelanoma skin cancers were not included. Native SEER
patient coding was used to determine the number of cancers
diagnosed in the same individual and cancer survival was
followed based on individual, not population, records. All
survival times were calculated from the date of diagnosis
of the bladder cancer and were censored at 5- and 10-year
endpoints. Patients were excluded from analysis if data were
not available for any of the following variables: age, sex, race,
grade, stage and year of diagnosis; additionally, due to the
small number of patients not classiﬁed in SEER as white,
black or Asian/Paciﬁc Islander these patients were excluded.
A total of 162,181 patients were included in the analysis, and
31,649 patients were excluded using these criteria.
The univariate Kaplan-Meier (KM) method was used
to estimate the survival rate and construct overall, cancer-
speciﬁc and bladder cancer-speciﬁc survival curves with data
censored at 5- and 10-year endpoints; a log-rank test was
used to determine P-values for these data. A multivariate
Coxproportionalhazardsmodelwasusedtocalculatehazard
ratios (HRs) of death for malignancy groups, adjusted for
age, sex, race, grade, stage, and year of diagnosis in order
to avoid confounding eﬀects of these variables. Univariate
and multivariate survival analyses were repeated with select
cohorts further partitioned based on the staging of their
bladder cancer as “low” (localized) or “high” (regional or
distant), according to the SEER Summary Staging classiﬁca-
tion (Table 1) .C a u s eo fd e a t h ,a sc o d e di nS E E R ,w a su s e d
in calculating cancer-speciﬁc and bladder cancer-speciﬁc
survivals. SAS 9.1 (SAS Institutes, Cary, NC) was used for
all statistical analyses.
The mean time between cancer diagnoses for the AB
and BS, cohorts was determined and compared using a
two-sided t-test; the same procedure was conducted to
determine the mean time between the diagnosis of bladder
cancer and death for the BO, AB, BS and ABS groups.
Lastly, SEER patient records were counted to determine the
most common nonbladder malignancies overall and in each
multiple malignancy cohort. All statistical tests were two-
sided, with a 0.05 level for statistical signiﬁcance.
3. Results
KM curves and univariate analyses show that the BO group
has an overall survival advantage at 5- and 10 years against
all multiple malignancy cohorts except for the BS group
(Figure 1, Table 2). Our ﬁnding that the BS group had the
greatest overall survival advantage at 5 years and yet the
BO group had this advantage at the 10-year endpoint led
us to construct a Cox proportional hazards model in order
to more eﬀectively analyze survival controlling for age, sex,
race, grade, stage, and yearof diagnosis. Multivariate analysis
conﬁrmed that BO patients have an overall and cancer-
speciﬁc survival advantage at 5- and 10 years over the AB
and ABS groups, but not over BS patients; BS patients had
an increased overall and decreased cancer-speciﬁc survival
compared to the BO group (Table 3).
We then partitioned BS and BO patients based on the
staging of their bladder cancer, according to the SEER
summary staging schema, and analyzed this data using a
multivariate Cox proportional hazards model. Our analyses
demonstrated a notable increase in survival among BS
patients withhigh-stagebladdercancerascomparedtohigh-
stage BO patients, while the opposite ﬁnding existed for the
low-stage cohorts where BO patients had a modest survival
advantage (Table 4, Figure 2). All survival diﬀerences were
statistically signiﬁcant with a P-value <. 001 (Tables 3-4).
Thus, it appears that BO patients with bladder cancer and
no other malignancies have a survival advantage over most
patients with multiple cancers. However, even after adjusting
for key diﬀerences between subgroups, patients who develop
at least one malignancy subsequent to the diagnosis of high-
stage bladder cancer have an improved survival compared to
patients with only high-stage bladder cancer.
In order to better understand survival trends in our
data we analyzed the time between diagnosis of bladder and
nonbladder malignancies for the AB and BS groups, as well
as the mean time to death following bladder cancer diagnosis
in all groups. For both of these measures we demonstrated
a signiﬁcant diﬀerence between all groups, with BS patients
having the longest time to death from the diagnosis ofAdvances in Urology 3
Table 1
Cohort deﬁnitions
BO Bladder cancer only: patients diagnosed with bladder cancer and no other cancers
AB Antecedent cancer(s) + bladder cancer: patients diagnosed with nonbladder malignancy before being diagnosed with
bladder cancer
BS Bladder cancer + subsequent cancer(s): patients diagnosed with nonbladder malignancy after being diagnosed with
bladder cancer
ABS Antecedent cancer + bladder cancer + subsequent cancer: patients diagnosed with nonbladder malignancy both before and
after being diagnosed with bladder cancer
SEER Summary Staging Deﬁnitions
Low-stage Localized disease
High-stage Regional or distant disease
Variables adjusted for in Cox model
Age Grade
Sex Stage
Race Year of diagnosis
Table 2: Survival rates for single and multiple malignancy cohorts, univariate analysis.
5-yr overall 10-yr overall 5-yr 10-yr 5-yr bladder 10-yr bladder
CA speciﬁc CA speciﬁc CA speciﬁc CA speciﬁc
BO n = 118,101 survival rate 0.61 0.44 0.78 0.73 0.80 0.76
AB n = 17,200 survival rate 0.52 0.27 0.61 0.39 0.91 0.86
P-value <. 001 <. 001 <. 001 <. 001 <. 001 <. 001
ABS n = 3,141 survival rate 0.46 0.26 0.62 0.52 0.82 0.77
P-value <. 001 <. 001 <. 001 <. 001 <. 001 <. 001
BS n = 23,739 survival rate 0.66 0.43 0.74 0.55 0.91 0.87
P-value <. 001 <. 001 <. 001 <. 001 <. 001 <. 001
P-values were all calculated against the corresponding survival rate of the bladder cancer only group. CA : cancer.
bladdercancerandhigh-stageBSpatientshavingtheshortest
time between cancer diagnoses (Table 5).
Additionally, we sought to determine the most common
nonbladder malignancies in patients with bladder cancer.
We evaluated data for the overall study population and
with patients partitioned by individual cohort in order
to investigate diﬀerences in patterns of carcinogenesis and
cancer diagnosis that might inﬂuence survival. The most
common nonbladder tumor in each of the three multiple
malignancy groups were prostate, followed by kidney in
the AB group and lung cancer in the BS and ABS groups
(Table 6).
4. Discussion
This study examines a population-based cancer registry,
comparing survival among bladder cancer patients with
single and multiple malignancies. Using SEER data collected
from 1973–2004, we determined that AB and ABS patients
have a distinct survival disadvantage when compared to BO
patients. Several factors may account for this ﬁnding. First,
patients with antecedent cancerswho develop bladder cancer
mayhaveinherentdeﬁcienciesinimmunesurveillance,DNA
repair, or epigenetic mechanisms leading to the development
of multiple malignancies [7]. Similar acquired defects may
also play a role in tumorgenesis in patients with previous
cancer diagnoses [8, 9]. Moreover, the development of these
deﬁciencies may be accelerated by smoking, obesity, and/or
treatment burden (chemotherapy or radiation) associated
with antecedent malignancies. Several well-known examples
illustrate this point.
Cyclophosphamide has a clear association with bladder
cancer—it is for this reason that urologists perform bladder
cancerscreeninginthispopulation[10].Inaddition,patients
whoreceiveradiationforthetreatmentofprostatecancerare
more likely to be diagnosed with bladder cancer, and more
likely to develop high-grade disease and have diminished
survival [11–13]. The development of subsequent cancer of
the bladder and other sites is seen predominantly among
patients who have undergone external beam radiation,
not brachytherapy [14]. These observations may partially
account for the negatively aﬀected survival among the AB
and ABS cohorts in this study. Of note, the most common
nonbladder malignancy in all multiple malignancy groups
was prostate cancer. Many patients in the BS group likely
had their prostate removed at the time of cystectomy. We
suspect that many of the prostate cancers diagnosed in this
group may have been found incidentally upon review of
surgical specimens. This may explain the high incidence
of subsequently diagnosed prostate cancers among a group4 Advances in Urology
Table 3: Survival rates and Cox hazard ratios representing AB, BS, ABS, and BO cohorts, multivariate analysis.
5-yr overall 10-yr overall 5-yr 10-yr 5-yr bladder 10-yr bladder
CA speciﬁc CA speciﬁc CA speciﬁc CA speciﬁc
AB (n = 17200) HR 1.409 1.384 1.788 1.842 0.892 0.906
95% CI (1.375, 1.444) (1.353, 1.416) (1.733, 1.845) (1.788, 1.898) (0.852, 0.933) (0.867, 0.947)
BS (n = 23739) HR 0.824 0.936 1.191 1.522 0.446 0.488
95% CI (0.804, 0.845) (0.917, 0.955) (1.156, 1.228) (1.484, 1.561) (0.424, 0.468) (0.467, 0.510)
ABS (n = 3141) HR 1.163 1.255 1.882 2.209 0.485 0.517
95% CI (1.102, 1.227) (1.198, 1.314) (1.769, 2.002) (2.093, 2.331) (0.425, 0.552) (0.458, 0.583)
BO (n = 118101) HR 1.0 1.0 1.0 1.0 1.0 1.0
HRs reported with 95% conﬁdence intervals (95% CI). All HRs calculated using BO cohort as the reference group. CA : cancer.
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Figure 1: Kaplan-Meier curves comparing (a) overall, (b) cancer-speciﬁc and (c) bladder cancer-speciﬁc survival of bladder cancer only and
BS patients with data censored at a 10-year endpoint.
where many have had their prostate removed. Future work
might employ SEER-Medicare data to examine the corre-
lation between prostate radiation and bladder carcinoma
and diﬀerential survival among patients with both these
malignancies.
Asidefromacquiredgeneticorimmunesurveillancedeﬁ-
ciencies, treatment burden from previous cancers may also
predispose patients to noncancer related comorbidities such
as chronic renal insuﬃciency and cardiovascular disease,
leading to decreased survival [15, 16]. These comorbidities
may also preclude the use of optimal cancer therapies in
patients with antecedent cancers, as they may be unable
or unwilling to undergo recommended treatments. This
factor almost certainly contributes to our observation of
diminished survival in the AB and ABS patient cohorts.
Althoughseeminglyintuitive,theseﬁndingsareimportantto
document because they can and should play a role in clinical
practice. Treatment decisions may be signiﬁcantly inﬂuenced
by such information, and counseling a patient with only
b l a d d e rc a n c e ri sq u i t ed i ﬀerent than a patient with bladder
cancer and an antecedent malignancy.
Contrary to our observations in the AB and ABS cohorts,
we observed that patients who develop a malignancy sub-
sequent to high-stage bladder cancer had improved overall,Advances in Urology 5
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Figure 2: (a) Kaplan-Meier curves illustrate an overall survival advantage at 10 years for the high-stage BS cohort when compared to its
respective high-stage bladder cancer only reference group. (b) The opposite ﬁnding existed for the low-stage patient groups, where the
bladder cancer only patients had a slightly increased survival.
Table 4: Stage adjusted survival rates and Cox hazard ratios for BO and BS cohorts, multivariate analysis.
5-yr overall 10-yr overall 5-yr 10-yr 5-yr bladder 10-yr bladder
CA speciﬁc CA speciﬁc CA speciﬁc CA speciﬁc
BO, low stage
(n = 81,129)
survival rate 0.73 0.53 0.90 0.85 0.92 0.88
HR 0.519 0.562 0.255 0.252 0.423 0.462
95% CI (0.497, 0.542) (0.540, 0.584) (0.242, 0.269) (0.240, 0.264) (0.396, 0.452) (0.433, 0.492)
BS, low stage
(n = 18,778)
survival rate 0.71 0.46 0.78 0.59 0.96 0.92
HR 0.537 0.642 0.596 0.738 0.223 0.285
95% CI (0.511, 0.564) (0.616, 0.670) (0.563, 0.631) (0.702, 0.775) (0.202, 0.245) (0.262, 0.311)
BO, high-stage
(n = 28,972)
survival rate 0.28 0.18 0.39 0.33 0.43 0.38
HR 1.802 1.682 1.700 1.546 2.644 2.586
95% CI (1.727, 1.880) (1.619, 1.748) (1.620, 1.783) (1.479, 1.615) (2.486, 2.813) (2.438, 2.744)
BS, high-stage
(n = 4,961)
survival rate 0.46 0.27 0.54 0.39 0.72 0.65
HRs reported with 95% conﬁdence intervals (95% CI). All HRs were calculated using the high-stage BS cohort as the reference group. SEER staging
classiﬁcation.
Table 5
(a) Time between bladder and nonbladder cancer diagnoses
Patient cohort Mean time between diagnoses ± SD (months)
AB
Overall 51.00 ±61.80
Low stage only 48.60 ±60.48
High-stage only 59.52 ±65.64
BS
Overall 56.28 ±63.48
Low stage only 63.36 ±65.88
High-stage only 29.16 ±51.36
P<. 001 for all intergroup comparisons.
(b) Time to death following diagnosis of bladder cancer
Patient cohort Mean time to death following
bladder cancer diagnosis (months)
BO 64.30
AB 43.21
BS 91.80
ABS 62.80
P<. 001 for all intergroup comparisons.6 Advances in Urology
Table 6: Most common nonbladder cancer diagnoses.
Overall (no. patients) AB BS ABS
(1) Prostate (16,160) (1) Prostate (6,568) (1) Prostate (8,214) (1) Prostate (1,378)
(2) Lung (6,992) (2) Renal (1,926) (2) Lung (4,912) (2) Lung (871)
(3) Renal (4,467) (3) Colon (1,646) (3) Renal (1,887) (3) Renal (654)
(4) Colon (4,061) (4) Breast (1,421) (4) Colon (1,855) (5) Colon (560)
(5) Breast (2,627) (5) Lung (1,209) (5) Breast (929)
cancer-speciﬁc and bladder cancer-speciﬁc survival when
compared to patients with only high-stage bladder cancer.
Althoughthisspeciﬁcﬁndingsupportsourinitialhypothesis,
we believe it is more likely the result of statistical and not
biological phenomena. The BS group has the longest mean
survival from the time of diagnosis of bladder cancer of
any group analyzed. This ﬁnding raises the possibility that
the reason for the BS group’s apparent survival advantage is
that the only patients included in the BS cohort are those
who live long enough to develop another cancer following
their bladder cancer diagnosis. This eﬀect is speciﬁcally
seen amongst high-stage cancer patients since they are most
likely to die of their disease; those receiving a second cancer
diagnosis may become part of the BS group since they
have outlived other high-stage bladder cancer patients, not
because their second malignancy confers a protective eﬀect.
While it is conceivable that a true biological phenomenon is
responsible for improved survival in some patient cohorts
with an increased cancer burden, this appears unlikely and
is not possible to fully determine given our data.
However, our study is not the ﬁrst to speculate on
improved outcomes among patients multiple malignancies
patients. Duchateau and Stokkel examined the prevalence
of multiple malignancies among patients with nonsmall
cell lung cancer (NSCLC) and compared survival between
patients with only NSCLC and various cohorts with NSCLC
and additional cancers [17]. They found that patients with
only NSCLC had the least favorable outcome, whereas those
with at least two cancers in addition to a primary diagnosis
of NSCLC had the greatest survival, and patients with one
cancer in addition to a primary NSCLC diagnosis had an
intermediate outcome. One weakness of this study may be
that approximately 25% of patients had multiple NSCLC
tumors that were included in the analysis as separately
diagnosed malignancies. The authors note that TNM stage
and treatment were comparable between all groups, and they
speculate that tumors in patients with multiple malignancies
may actually have distinct growth habits that are responsible
for the ﬁnding in this study.
Ouranalysissoughttocontrolforanumberofimportant
confounding variables, including: age, sex, race, grade,
stage, and year of diagnosis. It should be noted that while
we used the reported cause of death in SEER for our
analyses, it may be especially diﬃcult to assign a single
cause of death to a patient with multiple cancers. Also, since
SEER records cancer diagnoses just as they are reported,
it is possible that some reported second malignancies were
not diagnosed histologically and were actually mestastatic
lesions. Finally, we considered examining whether or not
diﬀerences in treatment existed between cohorts; however
data was inconsistent and not comprehensive within this
S E E Rd a t a s e t( S E E R - M e d i c a r ea l l o w sm o r ec o m p l e t ea c c e s s
to treatment data), and so we chose not to include it as a
variable. It would be useful to investigate possible treatment
and practice pattern diﬀerences between these cohorts in
a future study, as determining if such diﬀerences do exist
may help elucidate reasons for variable outcome between
cohorts.
The SEER Summary Staging classiﬁcation, which dif-
ferentiates low stage (local) and high-stage (regional or
distant) disease, is an important limitation of this study.
The American Joint Committee on Cancer (AJCC) method
is more commonly used in clinical settings, while SEER
has standardized and simpliﬁed staging to ensure consistent
deﬁnitions over time. AJCC staging is available for more
recent years through SEER, however, we chose to use
the SEER Summary Staging classiﬁcation because it was
the most consistent over the entire time period examined
(1973–2004). The limitation exists due to the variability of
patients in the high- and low-stage groups. For example,
“low-stage” encompasses noninvasive and localized invasive
disease (Ta, Tis, T1, and localized T2) in the same cohort,
even though the patient population within this cohort
is heterogeneous, as are treatment strategies; this makes
comparison between BO, AB, ABS, and BS cohorts by stage
more diﬃcult to interpret. Part of the explanation for the
survival advantage among high-stage BS patients relative
to high-stage BO patients may stem from this limitation.
Comparisonsbetweenoverallcohortsmayalsobeaﬀectedby
these groupings. Unfortunately, the extent of such an eﬀect
is hard to measure. Nevertheless, we believe that the sample
size of each cohort is large enough that the observations of
diminished survival among multiple malignancy patients are
valid.
Finally, we included all bladder cancer reported in SEER
as part of this investigation and did not diﬀerentiate urothe-
lial carcinoma from other bladder malignancies. Given
that urothelial carcinoma comprises a large proportion of
b l a d d e rc a n c e r( >90%), the eﬀect on this study is likely
minimal, but worthy of mention. Because cancers such as
small cell carcinoma or squamous cell carcinoma of the
bladder typically present at higher stages and carry worse
prognoses, it is possible that these are disproportionately
representedinthe“high-stage”groupings,therebynegatively
skewing survival data for these patients. Again, however,
the proportion of bladder cancers represented by these rareAdvances in Urology 7
diagnoses is small and unlikely to signiﬁcantly aﬀect the
study outcome.
It should also be noted that epidemiological information
regarding the diﬀerential survival of cancer cohorts may
not be appropriate to directly inform individual patient
care. However, these ﬁndings are important to shape future
research, better understand multiple malignancy patients,
and ultimately improve oncologic practice.
5. Conclusions
Bladder cancer patients with antecedent malignancies have
diminished survival when compared to patients with only
bladder cancer. An awareness and understanding of the
diﬀerential survival between such deﬁned cancer patient
cohorts can help to inform and improve future oncologic
research and our understanding of patients with multiple
malignancies. Future survival analyses among more homo-
geneous multiple malignancy populations will be important
in order to determine optimal treatment for their cancer(s)
and evidence-based information regarding their prognosis.
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